[
  {
    "ts": null,
    "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
    "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=b2e45727983e71cc1af9537d61e3c39ad47e6f1057981507a359f164f6815894",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753202160,
      "headline": "Amgen Inc. stock outperforms competitors on strong trading day",
      "id": 136043059,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=b2e45727983e71cc1af9537d61e3c39ad47e6f1057981507a359f164f6815894"
    }
  },
  {
    "ts": null,
    "headline": "How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings",
    "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
    "url": "https://finnhub.io/api/news?id=913955180113f4fcab0014eaae426c13bef0b776d7c4dfc0883e4c51f9e93496",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753189203,
      "headline": "How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings",
      "id": 136033511,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.",
      "url": "https://finnhub.io/api/news?id=913955180113f4fcab0014eaae426c13bef0b776d7c4dfc0883e4c51f9e93496"
    }
  },
  {
    "ts": null,
    "headline": "Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR | Roche, Amgen, and Johnson & Johnson at the Forefront: AnalystView Market Insights",
    "summary": "Bispecific T‑cell engagers now dominate oncology pipelines, with global trial activity up 256% since 2019. FDA has approved more than 15 such drugs, and U.S. spending is projected to hit $12.2billion by 2025, rising to over $50 billion by 2032.San Francisco, USA, July 22, 2025 (GLOBE NEWSWIRE) -- The global bispecific antibodies market is witnessing a transformative surge, projected to grow at an impressive compound annual growth rate (CAGR) of 40.10%, reaching a valuation of approximately USD 1",
    "url": "https://finnhub.io/api/news?id=72e8b4261ba13679e1808ad8c6859abc97a6a92ae2a03a1fa614e23f0eb34337",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753168800,
      "headline": "Bispecific Antibodies Market Set to Surge to $163.15 Billion by 2032, Driven by a Robust 40.1% CAGR | Roche, Amgen, and Johnson & Johnson at the Forefront: AnalystView Market Insights",
      "id": 136031286,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Bispecific T‑cell engagers now dominate oncology pipelines, with global trial activity up 256% since 2019. FDA has approved more than 15 such drugs, and U.S. spending is projected to hit $12.2billion by 2025, rising to over $50 billion by 2032.San Francisco, USA, July 22, 2025 (GLOBE NEWSWIRE) -- The global bispecific antibodies market is witnessing a transformative surge, projected to grow at an impressive compound annual growth rate (CAGR) of 40.10%, reaching a valuation of approximately USD 1",
      "url": "https://finnhub.io/api/news?id=72e8b4261ba13679e1808ad8c6859abc97a6a92ae2a03a1fa614e23f0eb34337"
    }
  }
]